

USSN: 10/091,258

Amdt. Dated: December 16, 2004

Reply to Office Action of August 25, 2004

Page 2 of 5

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method of treating or preventing intermittent claudication in a subject comprising the step of administering a therapeutically effective amount of a molecule selected from the group consisting of a glucagon-like peptide-1 (GLP-1), a biologically active fragment thereof having at least one of the following functions: regulating insulin secretion, inhibiting glucagon release, inhibiting gastric acid secretion, inhibiting gastric motility, suppressing food intake, suppressing food intake, enhancing peripheral glucose uptake, or reducing free fatty acid levels, variant, analog, mimetic, a GLP-1 receptor agonist or derivative thereof, and an exendin.
2. (Currently amended) A method of treating or preventing skeletal muscle injury caused by ischemia and/or reperfusion in a subject comprising the step of administering a therapeutically effective amount of a molecule selected from the group consisting of a GLP-1, a biologically active fragment thereof having at least one of the following functions: regulating insulin secretion, inhibiting glucagon release, inhibiting gastric acid secretion, inhibiting gastric motility, suppressing food intake, suppressing food intake, enhancing peripheral glucose uptake, or reducing free fatty acid levels, variant, analog, or derivative thereof, a GLP-1 receptor agonist, and an exendin.
3. (Previously presented) The method according to claim 1 or 2, wherein the molecule is selected from the group consisting of GLP-1(7-36)NH₂ (SEQ ID NO:4), GLP-1(7-37), exendin-3 and exendin-4.
4. (Previously presented) The method according to claim 1 or 2 wherein the GLP-1 molecule is selected from the group consisting of GLP-1(7-36)NH₂ (SEQ ID NO:4) and GLP-1(9-36)NH₂ (SEQ ID NO:6).

USSN: 10/091,258

Amdt. Dated: December 16, 2004

Reply to Office Action of August 25, 2004

Page 3 of 5

5. (Original) The method according to claim 1 or 2, wherein the subject is also administered free radical scavengers.
6. (Original) The method according to claim 5, wherein the free radical scavenger is selected from the group consisting of glutathione, melatonin, Vitamin E, and superoxide dismutase.
7. (Original) The method according to claim 1 or 2, wherein the subject is also administered glucose.
8. (Original) The method according to claim 7, wherein the subject is also administered potassium.
9. (Previously presented) The method according to claim 1 or 2, wherein the subject is suffering from Peripheral Vascular Disease (PVD).
10. (Original) The method according to claim 1 or 2, wherein the subject is human.
11. (Previously presented) The method according the claim 1 or 2, wherein the molecule is administered by an infusion pump or by subcutaneous injection of a slow release formulation of the molecule.